Subtype
Pancreatic Neoplasm
CI-CAN-00001356Explore in graph →
Non-malignant987 active trials8 approved drugs63 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001356Explore in graph →
Clinical trials
4,216 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05438667 | TCR-T Cell Therapy on Advanced Solid Tumors | terminated | Early Phase 1 | 1 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04930991 | High Dose Omeprazole in Patients With Pancreatic Cancer(OU202005AJ) | terminated | Early Phase 1 | 25 | University of OklahomaOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT05841706 | Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer | terminated | Early Phase 1 | 1 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT03492164 | In Vivo PARP-1 Expression With 18F-FTT PET/CT in Pancreatic Cancer | terminated | Early Phase 1 | 6 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT03519308 | A Pilot Study of Perioperative Nivolumab and Paricalcitol to Target the Microenvironment in Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03600623 | Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer | terminated | Early Phase 1 | 25 | University of Alabama at BirminghamOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03890198 | A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma | terminated | Early Phase 1 | 2 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Jul 2, 2020 | clinicaltrials |
| NCT00414570 | An Imaging Study of [18]F-fluoro-3'-Deoxy-3'-L-fluorothymidine ([18]F-FLT) in Patients With Locally Advanced or Metastatic Pancreatic Cancer Who Will be Treated With Gemcitabine or Other Nucleoside Analogs | terminated | Early Phase 1 | 11 | AHS Cancer Control AlbertaOTHER | 1 | Aug 28, 2019 | clinicaltrials |
| NCT03481920 | A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic Cancer | terminated | Early Phase 1 | 7 | PH Research, S.L.OTHER | 1 | Aug 22, 2019 | clinicaltrials |
| NCT01276613 | Tissue Pharmacokinetics of Intraoperative Gemcitabine in Resectable Adenocarcinoma of the Pancreas | terminated | Early Phase 1 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | May 2, 2019 | clinicaltrials |
| NCT00364364 | Safety Study to Determine the Appropriate Dose of Antibody Against Tumor Cells to Best Target Patients With Pancreatic Cancer. | terminated | Early Phase 1 | 2 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 18, 2019 | clinicaltrials |
| NCT00867126 | Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine | terminated | Early Phase 1 | 6 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 26, 2018 | clinicaltrials |
| NCT01962909 | Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer | terminated | Early Phase 1 | 3 | University of VirginiaOTHER | 1 | Mar 18, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Sep 1, 2026source: clinicaltrials